| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Veterinary Pathology, Vol 32, Issue 5 451-459, Copyright © 1995 by American College of Veterinary Pathologists
ARTICLES |
D. M. Hertzke, L. A. Cowan, P. Schoning and B. W. Fenwick
Department of Pathology and Microbiology, College of Veterinary Medicine, Kansas State University, Manhattan, USA.
Idiopathic cutaneous and renal glomerular vasculopathy (CRGV) (Alabama rot) is a potentially fatal disease of unknown etiology that affects the skin and kidneys of racing- and training-age Greyhounds. Ultrastructural examinations were performed on two healthy control Greyhounds and 12 Greyhounds diagnosed with CRGV based on the presence of characteristic, well-demarcated cutaneous ulcers of the extremities (12/12), thrombocytopenia (< 200,000 platelets/dl) (12/12), and acute renal insufficiency (BUN > 40 mg/dl, serum creatinine > 2.0 mg/dl) (7/12). Early glomerular ultrastructural changes included endothelial swelling, detachment, and necrosis; membranous whorl formation; and platelet adhesion and aggregation. Some capillaries were occluded with aggregated platelets, cellular fragments, and fibrin. Later changes included narrowing of capillary lumina and thickening of glomerular capillary walls by subendothelial accumulation of flocculent, amorphous, variable electron-dense material and occasionally erythrocytes, cellular processes, and fibrin. Glomerular endothelial cells were increased in number and plump, with villouslike cytoplasmic projections. Mesangial cell cytoplasmic processes occasionally were interposed between the endothelium and the basement membrane. No etiologic agents or electron-dense deposits typical of immune complexes were observed. Although the specific etiology was not determined, the ultrastructural changes suggest that glomerular endothelial damage is an important early event in the pathogenesis of CRGV.
This article has been cited by other articles:
![]() |
C. C. Toledo, T. J. Rogers, M. Svensson, R. Tati, H. Fischer, C. Svanborg, and D. Karpman Shiga Toxin-Mediated Disease in MyD88-Deficient Mice Infected with Escherichia coli O157:H7 Am. J. Pathol., November 1, 2008; 173(5): 1428 - 1439. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Tzipori, A. Sheoran, D. Akiyoshi, A. Donohue-Rolfe, and H. Trachtman Antibody Therapy in the Management of Shiga Toxin-Induced Hemolytic Uremic Syndrome Clin. Microbiol. Rev., October 1, 2004; 17(4): 926 - 941. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. L. SIEGLER, T. J. PYSHER, V. L. TESH, and F. B. TAYLOR JR. Response to Single and Divided Doses of Shiga Toxin-1 in a Primate Model of Hemolytic Uremic Syndrome J. Am. Soc. Nephrol., July 1, 2001; 12(7): 1458 - 1467. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. P. Nataro and J. B. Kaper Diarrheagenic Escherichia coli Clin. Microbiol. Rev., January 1, 1998; 11(1): 142 - 201. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |